Health State Utilities Associated with False-Positive Cancer Screening Results [0.03%]
癌症筛查假阳性结果相关的健康状态效用值
Louis S Matza,Timothy A Howell,Eric T Fung et al.
Louis S Matza et al.
Introduction: Early cancer detection can significantly improve patient outcomes and reduce mortality rates. Novel cancer screening approaches, including multi-cancer early detection tests, have been developed. Cost-utilit...
Cost-Utility Analysis of Total Ankle Replacement Compared with Ankle Arthrodesis for Patients Aged 50-85 Years with End-Stage Ankle Osteoarthritis: The TARVA Study [0.03%]
对于50至85岁终末期踝关节骨关节炎患者，全踝关节置换术与踝关节融合术的费用效益分析：TARVA研究
Andrew J Goldberg,Ekaterina Bordea,Kashfia Chowdhury et al.
Andrew J Goldberg et al.
Background: Patients with end-stage ankle osteoarthritis suffer from reduced mobility and quality of life and the main surgical treatments are total ankle replacement (TAR) and ankle fusion (AF). ...
Understanding the Natural History of Chronic Hepatitis D: Proposal of a Model for Cost-Effectiveness Studies [0.03%]
慢性丁型肝炎自然史的理解：成本效益研究的模型提案
Ankita Kaushik,Geoffrey Dusheiko,Chong Kim et al.
Ankita Kaushik et al.
Background: As new therapeutic options become available, better understanding the potential impact of emerging therapies on clinical outcomes of hepatits D virus (HDV) is critical. ...
Economic Evaluation of a Personalized Nutrition Plan Based on Omic Sciences Versus a General Nutrition Plan in Adults with Overweight and Obesity: A Modeling Study Based on Trial Data in Denmark [0.03%]
基于omics科学的个性化营养计划与通用营养计划的成本效益分析：基于丹麦临床试验数据的模拟研究
Milanne Maria Johanna Galekop,Carin Uyl-de Groot,William Ken Redekop
Milanne Maria Johanna Galekop
Background: Since there is no diet that is perfect for everyone, personalized nutrition approaches are gaining popularity to achieve goals such as the prevention of obesity-related diseases. However, appropriate choices a...
The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals [0.03%]
西班牙提高丙型肝炎检测和治疗策略效率以实现消除目标的效果分析
Jose Luis Calleja,Jaime Espin,Ankita Kaushik et al.
Jose Luis Calleja et al.
Background: In 2015, Spain launched a national eradication strategy for hepatitis C virus (HCV), resulting in the highest treatment rate in Europe and substantial reductions in HCV prevalence. However, to achieve the goal...
The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain [0.03%]
英国、法国、德国、意大利和西班牙的卫生技术评估机构对间接治疗类比方法在肿瘤学中应用的接受度
Bérengère Macabeo,Théophile Rotrou,Aurélie Millier et al.
Bérengère Macabeo et al.
Introduction: Randomized controlled trials (RCTs) are the gold standard when comparing treatment effectiveness, and Health Technology Assessment (HTA) agencies state a clear preference for such direct comparisons. When th...
Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden [0.03%]
BRCA1/2基因突变高危HER2阴性早期乳腺癌综合辅助治疗奥拉帕利与观察等待的经济学分析-瑞典研究
Maria Polyzoi,Mattias Ekman,Anja Reithmeier et al.
Maria Polyzoi et al.
Introduction: This study evaluated the cost effectiveness of adjuvant olaparib versus watch and wait (WaW) in patients with germline breast cancer susceptibility gene 1/2 (gBRCA1/2)-mutated, high-risk, human epidermal gro...
An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund [0.03%]
英国抗癌药物基金不确定性分析及数据收集协议研究
Laura A Trigg,Maxwell S Barnish,Samuel Hayward et al.
Laura A Trigg et al.
Background: Managed Access Agreements (MAAs) are a commercial arrangement that provide patients earlier access to innovative health technologies while uncertainties in the evidence base are resolved through data collectio...
United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument [0.03%]
美国版本的功能评估癌症疗法八维度(FACTVS-8D)，一种基于癌症的偏好型生命质量测量工具
Madeleine T King,D A Revicki,R Norman et al.
Madeleine T King et al.
Objectives: To develop a value set reflecting the United States (US) general population's preferences for health states described by the Functional Assessment of Cancer Therapy (FACT) eight-dimensions preference-based mul...
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15 [0.03%]
对NICE高专科技评估15号的部分评估中用于治疗无症状期脊髓性肌萎缩症的onasemnogene abeparvovec的外部评估小组观点的更正
Marty Chaplin,Rebecca Bresnahan,Nigel Fleeman et al.
Marty Chaplin et al.
Published Erratum
PharmacoEconomics - open. 2023 Nov;7(6):1015. DOI:10.1007/s41669-023-00462-7 2023